Bioventix Announces Licence Agreement with Dade Behring

Farnham, Surrey, UK: 2 October 2006

Bioventix announced today completion of a licence agreement with Dade Behring covering high affinity sheep monoclonal antibody (SMA) secreting cell lines created by Bioventix for use by Dade Behring. Under a previous research contract, Bioventix supplied a panel of SMA’s to Dade Behring for possible applications on its clinical chemistry analysers. Following successful trials of these antibodies on Dade Behring platforms, development activities have now commenced.
Peter Harrison, Managing Director of Bioventix commented “We are delighted that our SMA technology has found another niche in such a key diagnostic application. It has been very rewarding to have worked on such an important project with Dade Behring and to have once again demonstrated the unique properties of the SMA’s made in our laboratory”

ABOUT BIOVENTIX

Bioventix is a privately owned antibody creation, engineering and production company based in Farnham, Surrey, UK. Scientists at Bioventix have pioneered the creation of sheep hybridomas and the production of very high affinity sheep monoclonal antibodies secreted by such cell lines. These antibodies have particular niche uses in various diagnostic applications and Bioventix supplies such high performance antibodies to the majority of multinational clinical diagnostics companies. In addition to diagnostic applications, Bioventix has an active program using its SMA technology in bio-terror counter-measure applications. Bioventix also has a research project featuring the use of multimeric bispecific antibody entities in cancer therapy. For further information, please visit www.bioventix.com
For further information, contact Peter Harrison:
(tel: 44 1252 728001, e-mail: peter.Harrison@bioventix.com )

<<< back to news